Myovant Sciences Announces European Commission Approval for : vimarsana.com

ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure European...

Related Keywords

Liechtenstein , United States , Norway , Iceland , Switzerland , David Marek , Uneek Mehra , Juan Camilo Arjona Ferreira , Myovant Sciences Media Contact , Linkedin , European Commission , Myovant Sciences , Drug Administration , Exchange Commission , Myovant Sciences Investor Contact , Public Affairs , Sumitomo Pharma Co Ltd , Corporate Communications , Myovant Sciences Inc , European Union , Sumitovant Biopharma Ltd , Chief Medical Officer , Chief Executive Officer , New England Journal , New Drug Application , Private Securities Litigation Reform Act , Myovant Science , United States Securities , Myovant Science Quarterly Report , Sciences Investor Contact , Sciences Media Contact , Nyse Myov , Yovant Sciences , Nc , Yovant , Ealthcare ,